Skip to Content

Data show that the combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in type 1 and type 2 diabetes patients (6 December 2011)



Dubai, UAE – Insulin degludec / insulin aspart reduced rates of hypoglycaemia by 58%* in people with type 2 diabetes compared to biphasic insulin aspart when dosed twice-daily. This is according to a study released today by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress.1

In the study, insulin degludec/insulin aspart reduced the overall occurrence of hypoglycaemia during the day as well as at night (occurring between 23:00 and 05.59).  Improvements in fasting plasma glucose (FPG) were also seen, with levels significantly lower in the insulin degludec/insulin aspart group vs  biphasic insulin aspart (6.4 vs. 7.5 mmol/l**). The study also found that insulin degludec/insulin aspart was well tolerated and provided comparable overall glycaemic control to biphasic insulin aspart.1

“The unique way in which insulin degludec/insulin aspart works, with the basal insulin providing an ultra-long and steady action profile, plus a bolus boost of insulin aspart, provides a simple way to introduce mealtime dosing at any meal,” said Dr Alan Moses, Corporate Vice President and Global Chief Medical Officer, Novo Nordisk. “These benefits, along with the reduced risk of hypoglycaemia and improved FPG shown in these studies, are very promising for people living with diabetes.”

A second study also presented today showed that rates of hypoglycaemia at night were reduced by 37%*** in people with type 1 diabetes using once-daily insulin degludec/insulin aspart (with additional rapid-acting mealtime insulin doses for the remaining meals), compared to those using once-daily insulin detemir plus rapid-acting insulin at all main meals.2



*     Estimated rate ratio (ERR): 0.42 [0.23; 0.75]
**    Estimated treatment difference (ETD):-0.99mmol/l [-1.68; -0.29])
***    ERR: 0.63 [95% CI: 0.49; 0.81] p=0.0003

Insulin degludec/insulin aspart, in development by Novo Nordisk, will, pending approval, be the only soluble insulin combination of ultra-long-acting basal insulin degludec and rapid-acting insulin, insulin aspart. Clinical studies have shown that it provides fasting plasma glucose control with significantly less hypoglycaemia compared to premix insulin.1

Insulin degludec has a unique, slow rate of absorption which provides a flat and stable action profile.3,4  In several clinical trials, insulin degludec has demonstrated effective glycaemic control and improvements in both HbA1c and FPG.5-7 It has also demonstrated a significantly lower rate of hypoglycaemia when compared to insulin glargine.5-9

Both insulin degludec and insulin degludec/insulin aspart were submitted to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) earlier this year for regulatory review. 

Further information:




Katrine Sperling

Klaus Bülow Davidsen

Tel: (+45) 4442 6718

Tel: (+45) 4442 3176


Ambre Morley

Frank Daniel Mersebach

Tel: (+1) 609 216 5240

Tel: (+45) 4442 0604


Lars Borup Jacobsen


Tel: (+45) 3075 3479


Jannick Lindegaard


Tel: (+1) 609 786 4575

Posted: December 2011